{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:23:16Z","timestamp":1791411796385,"version":"4.3.3"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,5]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Renin-angiotensin system inhibitor use was not associated with slowed GFR decline in sickle cell disease.<\/jats:p>\n <\/jats:list-item>\n \n This null association did not change after excluding low-dose renin-angiotensin system inhibitors or including an interaction term with sickle cell disease therapies.<\/jats:p>\n <\/jats:list-item>\n \n Our findings highlight the limitations of real-world data and underscore the urgent need for prospective trials and novel therapeutics.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Sickle cell disease (SCD) is associated with accelerated kidney function decline, with no proven effective therapies. We examined the associations between treatment with renin-angiotensin system inhibitors (RASi) and eGFR decline in SCD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This two-center observational study used electronic health record data of adult, Black patients with SCD (by hemoglobin electrophoresis), and \u22651-year follow-up between 2010 and 2024. We compared incident RASi users (exposure) to no treatment (reference). We created 1:1 propensity score-matched cohorts, balancing on demographics, vital signs, comorbidities, medications, and laboratory values. The primary end point was the difference in the mean change in eGFR per year, analyzing only chronic slopes (\u226590 days postindex date) using linear mixed models on the matched cohorts. Sensitivity analyses were performed excluding patients with missing albuminuria and excluding low-dose RASi. Effect modification by SCD-modifying therapies was also examined.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Matched cohorts identified were primary analysis (358 patients), excluding missing albuminuria data (262 patients), and excluding low-dose RASi (270 patients). All cohorts achieved optimal standardized mean differences <0.2. After multivariable adjustment, there was no significant difference in eGFR decline between RASi and the reference in the primary cohort (\u22120.15 ml\/min per year; 95% confidence interval [CI], \u22121.67 to +1.36;\n P<\/jats:italic>\n = 0.84), the sensitivity analysis cohort excluding missing albuminuria data (+0.89 ml\/min per year; 95% CI, \u22120.86 to +2.63;\n P<\/jats:italic>\n = 0.32), and the sensitivity analysis cohort excluding low-dose RASi (+0.78 ml\/min per year; 95% CI, \u22121.12 to +2.67;\n P<\/jats:italic>\n = 0.42). All\n P<\/jats:italic>\n values for interaction terms between RASi and SCD-modifying therapies in all models were >0.05.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this large, real-world cohort of patients with SCD, RASi use was not associated with slowed eGFR decline. These findings underscore the limitations of observational data and highlight the urgent need for prospective trials to identify effective GFR-preserving therapies for this high-risk population.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000001116","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:00:54Z","timestamp":1769014854000},"page":"1056-1064","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Kidney Function Decline in Sickle Cell Disease"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1785-960X","authenticated-orcid":false,"given":"Kabir O.","family":"Olaniran","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecia C.","family":"Nero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-3414","authenticated-orcid":false,"given":"Orson W.","family":"Moe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9531-1749","authenticated-orcid":false,"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Department of Population and Data Sciences, Peter O\u2019Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-4729","authenticated-orcid":false,"given":"S. Susan","family":"Hedayati","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Department of Medicine, Stony Brook University, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"16","key":"B1-20260601","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med."},{"issue":"6","key":"B2-20260601","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"B3-20260601","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-022-00540-9","article-title":"The nephropathy of sickle cell trait and sickle cell disease","volume":"18","author":"Ataga","year":"2022","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"B4-20260601","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol."},{"issue":"10","key":"B5-20260601","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA."},{"issue":"7","key":"B6-20260601","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/bloodadvances.2019001378","article-title":"Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study","volume":"4","author":"Niss","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"B7-20260601","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1681\/ASN.2019050502","article-title":"Kidney function decline among black patients with sickle cell trait and sickle cell disease: an observational cohort study","volume":"31","author":"Olaniran","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B8-20260601","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2215\/CJN.06960520","article-title":"Acute kidney injury among black patients with sickle cell trait and sickle cell disease","volume":"16","author":"Olaniran","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B9-20260601","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2018.12.027","article-title":"Progressive decline in estimated GFR in patients with sickle cell disease: an observational cohort study","volume":"74","author":"Derebail","year":"2019","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"B10-20260601","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1002\/ajh.24810","article-title":"Losartan for the nephropathy of sickle cell anemia: a phase-2, multicenter trial","volume":"92","author":"Quinn","year":"2017","journal-title":"Am J Hematol."},{"issue":"14","key":"B11-20260601","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJM199204023261402","article-title":"Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme","volume":"326","author":"Falk","year":"1992","journal-title":"N Engl J Med."},{"issue":"4","key":"B12-20260601","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(98)00056-4","article-title":"A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia","volume":"104","author":"Foucan","year":"1998","journal-title":"Am J Med."},{"issue":"6","key":"B13-20260601","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1681\/ASN.2014111126","article-title":"Six months of hydroxyurea reduces albuminuria in patients with sickle cell disease","volume":"27","author":"Bartolucci","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B14-20260601","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bcmd.2017.09.006","article-title":"Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia","volume":"69","author":"Yee","year":"2018","journal-title":"Blood Cells Mol Dis."},{"issue":"5","key":"B15-20260601","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0002-9343(99)80341-6","article-title":"Enalapril reduces the albuminuria of patients with sickle cell disease","volume":"98","author":"Aoki","year":"1995","journal-title":"Am J Med."},{"issue":"4","key":"B16-20260601","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s11606-019-05555-w","article-title":"Validity of international classification of diseases codes for sickle cell trait and sickle cell disease","volume":"35","author":"Olaniran","year":"2020","journal-title":"J Gen Intern Med."},{"issue":"9","key":"B17-20260601","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1291\/hypres.31.1711","article-title":"Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"31","author":"Shimizu","year":"2008","journal-title":"Hypertens Res."},{"issue":"23","key":"B18-20260601","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation."},{"issue":"7","key":"B19-20260601","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med."},{"issue":"19","key":"B20-20260601","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"B21-20260601","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2019060605","article-title":"Estimating urine albumin-to-creatinine ratio from protein-to-creatinine ratio: development of equations using same-day measurements","volume":"31","author":"Weaver","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B22-20260601","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B23-20260601","doi-asserted-by":"crossref","first-page":"100983","DOI":"10.1016\/j.blre.2022.100983","article-title":"Determinants of severity in sickle cell disease","volume":"56","author":"Rees","year":"2022","journal-title":"Blood Rev."},{"issue":"12","key":"B24-20260601","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.34067\/KID.0000000000000541","article-title":"Hyperkalemia and risk of chronic kidney disease progression: a propensity score matched analysis","volume":"5","author":"Agiro","year":"2024","journal-title":"Kidney360."},{"issue":"1","key":"B25-20260601","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2215\/CJN.12950921","article-title":"Optimizing renin-angiotensin system inhibitor use in CKD","volume":"17","author":"Chang","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B26-20260601","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"issue":"2","key":"B27-20260601","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.15651","article-title":"Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease","volume":"184","author":"Thrower","year":"2019","journal-title":"Br J Haematol."},{"issue":"2","key":"B28-20260601","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia","volume":"102","author":"Pegelow","year":"1997","journal-title":"Am J Med."},{"issue":"2","key":"B29-20260601","doi-asserted-by":"crossref","first-page":"e0263424","DOI":"10.1371\/journal.pone.0263424","article-title":"Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition","volume":"17","author":"Brito","year":"2022","journal-title":"PLoS One."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:56:23Z","timestamp":1786478183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001116"}},"subtitle":["Associations with Renin-Angiotensin System Inhibitors"],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001116","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-07-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}